Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats
10.1016/j.afos.2023.11.002
- Author:
Shun IGARASHI
1
;
Yuji KASUKAWA
;
Koji NOZAKA
;
Hiroyuki TSUCHIE
;
Kazunobu ABE
;
Hikaru SAITO
;
Ryo SHOJI
;
Fumihito KASAMA
;
Shuntaro HARATA
;
Kento OKAMOTO
;
Keita OYA
;
Naohisa MIYAKOSHI
Author Information
1. Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan
- Publication Type:Original article
- From:Osteoporosis and Sarcopenia
2023;9(4):121-130
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:Chronic kidney disease (CKD) complicated by secondary hyperparathyroidism (SHPT) is associated with an increased risk of fragility fractures. Etelcalcetide (EC) is a treatment for SHPT that reduces serum parathyroid hormone (PTH) levels. However, the effects of combined treatment with osteoporosis drugs such as teriparatide (TPTD) remain unclear. This study investigates the combined effects of EC and TPTD on bone in CKD model rats.
Methods:The CKD model was established in 8-week-old male Wistar rats by feeding them a 0.75% adenine diet for 4 weeks. At 20 weeks of age, the rats were divided into 4 groups (n = 9–10 in each group): CKD group (vehicle administration), TPTD group (30 μg/kg, 3 times/week), EC group (0.6 mg/kg, daily), and Comb group (TPTD and EC combined). EC was injected for 12 weeks starting at 20 weeks of age, and TPTD was injected for 8 weeks starting at 24 weeks of age. After treatment, the followings were evaluated: bone mineral density, bone strength, biochemical tests, bone and fat histomorphometry, and micro-computed tomography.
Results:In CKD model rats, the combination of EC and TPTD was more effective in increasing cortical bone thickness and bone strength and inhibiting porosity. In addition, the combined treatment decreased bone marrow adiposity and fibrosis, and it increased bone mass and improved bone microstructure in trabecular bone.
Conclusions:With the observed benefits such as improved bone mass, bone strength, structural properties, and bone marrow adiposity, combination therapy may be a potential way to improve bone fragility in CKD.
